Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cingulate Inc. (CING : NSDQ)

• Company Description    Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release(TM) drug delivery platform technology to build and advance a pipeline of pharmaceutical products. Cingulate Inc. is based in KANSAS CITY, Kan. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $3.73 Daily Weekly Monthly 20 Day Moving Average: 248,371 shares Shares Outstanding: 5.41 (millions) Market Capitalization: $20.19 (millions) Beta: -0.74 52 Week High: $6.01 52 Week Low: $3.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.25% -11.62% 12 Week -7.67% -11.50% Year To Date -24.34% -33.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1901 W. 47TH PLACE - KANSAS CITY,KS 66205 USA ph: 913-942-2300 fax: - ir@cingulate.com http://www.cingulate.com

• General Corporate Information    Officers Shane J. Schaffer - Chief Executive Officer and Chairman of the Board Laurie A. Myers - Executive Vice President and Chief Operating Offic Jennifer L. Callahan - Senior Vice President and Chief Financial Officer Jeffrey S. Ervin - Director Bryan Lawrence - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 17248W303 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 5.41 Most Recent Split Date: 8.00 (0.08:1) Beta: -0.74 Market Capitalization: $20.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.63 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.48 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 80.07% vs. Previous Quarter: -4.81% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -232.16 03/31/25 - -229.78 ROA 09/30/25 - - 06/30/25 - -132.07 03/31/25 - -142.28 Current Ratio 09/30/25 - - 06/30/25 - 1.52 03/31/25 - 1.87 Quick Ratio 09/30/25 - - 06/30/25 - 1.52 03/31/25 - 1.87 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 1.07 03/31/25 - 1.50 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.16 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 13.48

Powered by Zacks Investment Research ©